A phase III trial ancillary analysis found the Decipher Prostate Test predicts which intermediate-risk prostate cancer ...

Stereotactic body radiation therapy significantly improved quality of life outcomes, including urinary incontinence and ...

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...

There is a moment in a prostate cancer consultation when I sometimes wish I could slow time down. The patient has already been through the blood test, the scan and ...

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging. Melbourne (Australia) and Indianapolis, IN (United States) \| September 30, 2026. FDA Fast T ...

The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510 (k) supported by the HYDROSPACE trial.

NRG-GU005: SBRT vs Moderately Hypofractionated IMRT in Localized Prostate Cancer / cancer, cancer care, Cancer research, cancer treatment, clinical trials, ...

“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026. SOU ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...

September is Prostate Cancer Awareness Month, highlighting the importance of understanding prostate cancer screenings, including what a prostate-specific antigen (PSA) number actually means, when test ...

For men, taking measure of your prostate health is a lot like tracking your golf games — and just as personal, Dr. Curtis ...